Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Rating of Buy by Brokerages

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) have received an average recommendation of “Buy” from the six ratings firms that are currently covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have covered the stock in […]

Related Keywords

Cyrus Harmon ,Davidc Myles ,Credit Suisse Group ,Geode Capital Management ,Nasdaq ,Institutional Trading Of Olema Pharmaceuticals ,Dimensional Fund Advisors ,Olema Pharmaceuticals ,Olema Pharmaceuticals Stock ,Analyst Recommendations For Olema Pharmaceuticals ,Millennium Management ,Olema Pharmaceuticals Inc ,Insider Activity At Olema Pharmaceuticals ,Jpmorgan Chase Co ,Blackrock Inc ,Vanguard Group Inc ,News Ratings For Olema Pharmaceuticals Daily ,Olema Pharmaceuticals Company Profile ,Securities Exchange Commission ,Get Free Report ,Suisse Group ,Director Cyrus Harmon ,Exchange Commission ,Fund Advisors ,Capital Management ,Get Free ,Olema Pharmaceuticals Daily ,Nasdaq Olma ,Dolma ,Medical ,Ratings ,Consensus ,